[go: up one dir, main page]

AU2001294511A1 - New strategy for leukemia therapy - Google Patents

New strategy for leukemia therapy

Info

Publication number
AU2001294511A1
AU2001294511A1 AU2001294511A AU9451101A AU2001294511A1 AU 2001294511 A1 AU2001294511 A1 AU 2001294511A1 AU 2001294511 A AU2001294511 A AU 2001294511A AU 9451101 A AU9451101 A AU 9451101A AU 2001294511 A1 AU2001294511 A1 AU 2001294511A1
Authority
AU
Australia
Prior art keywords
new strategy
leukemia therapy
leukemia
therapy
strategy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294511A
Inventor
Paolo Vigneri
Jean Y. J. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001294511A1 publication Critical patent/AU2001294511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2001294511A 2000-06-30 2001-06-29 New strategy for leukemia therapy Abandoned AU2001294511A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21559500P 2000-06-30 2000-06-30
US60215595 2000-06-30
PCT/US2001/020602 WO2002000024A1 (en) 2000-06-30 2001-06-29 New strategy for leukemia therapy

Publications (1)

Publication Number Publication Date
AU2001294511A1 true AU2001294511A1 (en) 2002-01-08

Family

ID=22803600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294511A Abandoned AU2001294511A1 (en) 2000-06-30 2001-06-29 New strategy for leukemia therapy

Country Status (3)

Country Link
US (2) US7238525B2 (en)
AU (1) AU2001294511A1 (en)
WO (1) WO2002000024A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028381A2 (en) * 2000-10-05 2002-04-11 Daley George Q Methods of inducing cancer cell death and tumor regression
WO2002092091A1 (en) * 2001-05-16 2002-11-21 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
US6878697B2 (en) 2001-06-21 2005-04-12 Ariad Pharmaceuticals, Inc. Phenylamino-pyrimidines and uses thereof
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
DE10248751A1 (en) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslocation molecules and their use
US20050203174A1 (en) * 2004-03-09 2005-09-15 Kosan Biosciences, Inc. Combination therapies using leptomycin B
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
JP2009502206A (en) * 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド Modulation of Kv1.1 voltage-gated potassium channels in T cells to regulate tumor necrosis factor alpha (TNF-α) synthesis and secretion, and humans through harmful high or low levels of TNF-α Treatment of disease or injury
US8003687B2 (en) 2005-09-12 2011-08-23 Kosan Biosciences Incorporated Esters of compounds in the leptomycin family
BRPI0710675A2 (en) * 2006-04-07 2011-08-23 Novartis Ag use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
CN101711154A (en) * 2007-02-26 2010-05-19 科森生物科学公司 carbamate compound
EA029131B1 (en) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2010039275A1 (en) * 2008-10-03 2010-04-08 Oligonix, Inc. Method, array and system for detecting intergenic fusions
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers

Also Published As

Publication number Publication date
US20070299097A1 (en) 2007-12-27
US20030162740A1 (en) 2003-08-28
WO2002000024A8 (en) 2002-03-21
US7238525B2 (en) 2007-07-03
WO2002000024A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2002222853A1 (en) Therapeutic compounds
AU2002225730A1 (en) Compounds
AU2001280796A1 (en) Electrowetting-driven micropumping
AU2001262847A1 (en) Language-understanding
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001220246A1 (en) Neckphone
AU2001294511A1 (en) New strategy for leukemia therapy
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001265089A1 (en) Rc-timer scheme
AU2001258349A1 (en) Bisacylguanidine
AU4430701A (en) Compounds for targeting
AUPQ661800A0 (en) Insulin-potentiating compounds
AU2001220281A1 (en) Rollerboard for road-skiing
AU2001258924A1 (en) Microsatellite-aflp
AU2002225724A1 (en) Motilide compounds
EP1185135A3 (en) Chinguard for headphone
AU2002220684A1 (en) Fap-alpha-activated anti-tumor compounds
AU2002217285A1 (en) Compounds
AU2001246864A1 (en) Hypotensors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001262711A1 (en) Cytoprotectors
AU2001260192A1 (en) Glycinamides
AU2001292897A1 (en) Novel therapy
AU7634201A (en) 6-methyl-4-trihalomethyltriazine compounds